Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 2.08% is 164% above its 5-year average of 0.79%, near the high end of its 5-year range (-85.38%–2.96%).
3.99% below its 12-month average of 2.17%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 2.39%.
EBITDA MARGIN
2.08%
EBITDA MARGIN AVG TTM
2.17%
EBITDA MARGIN AVG 3Y
1.73%
EBITDA MARGIN AVG 5Y
0.79%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.99%
CURRENT VS 3Y AVG
+20.57%
CURRENT VS 5Y AVG
+163.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Privia Health Group, Inc.
Market Cap
$2.56B
EBITDA Margin
2.08%
TTM Avg
2.17%
3Y Avg
1.73%
5Y Avg
0.79%
Market Cap
$2.58B
EBITDA Margin
-1001.92%
TTM Avg
-694.29%
3Y Avg
-672.56%
5Y Avg
-672.56%
Market Cap
$2.60B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.60B
EBITDA Margin
11.52%
TTM Avg
13.31%
3Y Avg
15.86%
5Y Avg
16.56%
Market Cap
$2.47B
EBITDA Margin
7.61%
TTM Avg
16.05%
3Y Avg
16.23%
5Y Avg
20.37%
Market Cap
$2.66B
EBITDA Margin
11.88%
TTM Avg
11.88%
3Y Avg
7.44%
5Y Avg
-2.29%
Market Cap
$2.70B
EBITDA Margin
17.42%
TTM Avg
19.36%
3Y Avg
20.74%
5Y Avg
18.34%
Market Cap
$2.69B
EBITDA Margin
-1067.75%
TTM Avg
-2196.34%
3Y Avg
-1532.38%
5Y Avg
-1148.77%
Market Cap
$2.71B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | $2.56B | 2.08% | 2.17% | 1.73% | 0.79% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.58B | -1001.92% | -694.29% | -672.56% | -672.56% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | -270.04% | -444.88% | -365.27% | -89273.54% |
| Neogen Corporation (NEOG)vs › | $2.60B | 11.52% | 13.31% | 15.86% | 16.56% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.47B | 7.61% | 16.05% | 16.23% | 20.37% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 11.88% | 11.88% | 7.44% | -2.29% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 17.42% | 19.36% | 20.74% | 18.34% |
| Precigen, Inc. (PGEN)vs › | $2.69B | -1067.75% | -2196.34% | -1532.38% | -1148.77% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -755.79% | -753.93% | -709.93% | -1157.85% |
Gross Margin
7.6%
EBITDA Margin
2.1%
Operating Margin
1.9%
Net Margin
1.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 2.39% |
| 2026-03-31 | 1.77% |
| 2025-12-31 | 2.57% |
| 2025-09-30 | 2.96% |
| 2025-06-30 | 1.14% |
| 2025-03-31 | 1.48% |
| 2024-12-31 | 1.54% |
| 2024-09-30 | 1.74% |
| 2024-06-30 | 1.64% |
| 2024-03-31 | 0.64% |
| 2023-12-31 | 0.72% |
| 2023-09-30 | 1.74% |
| 2023-06-30 | 2.10% |
| 2023-03-31 | 2.09% |
| 2022-12-31 | 0.93% |
| 2022-09-30 | -1.00% |
| 2022-06-30 | -1.22% |
| 2022-03-31 | -3.32% |
| 2021-12-31 | -6.62% |
| 2021-09-30 | -4.91% |
| 2021-06-30 | -85.38% |
| 2021-03-31 | 3.91% |
| 2020-12-31 | 2.16% |
| 2020-09-30 | 4.34% |
| 2020-06-30 | 3.70% |
| 2020-03-31 | 3.20% |
